STEMI patients with active COVID-19 had significantly higher in-hospital mortality compared to those without COVID-19 (21.7% vs 9.3%; OR 2.72; 95% CI 1.25-5.82; p=0.012).
Observational (n=788)
Sí
Does the COVID-19 pandemic and active COVID-19 infection worsen outcomes in STEMI patients undergoing primary percutaneous coronary intervention?
STEMI patients with concomitant COVID-19 infection have significantly higher in-hospital mortality and ICU admission rates, despite maintained PPCI pathways during the pandemic.
Estimación del efecto: OR 2.72 (95% CI 1.25 to 5.82)
Tasa de eventos absoluta: 21.7% vs 9.3%
valor p: p=0.012
OBJECTIVES: To understand the impact of COVID-19 on delivery and outcomes of primary percutaneous coronary intervention (PPCI). Furthermore, to compare clinical presentation and outcomes of patients with ST-segment elevation myocardial infarction (STEMI) with active COVID-19 against those without COVID-19. METHODS: We systematically analysed 348 STEMI cases presenting to the PPCI programme in London during the peak of the pandemic (1 March to 30 April 2020) and compared with 440 cases from the same period in 2019. Outcomes of interest included ambulance response times, timeliness of revascularisation, angiographic and procedural characteristics, and in-hospital clinical outcomes RESULTS: There was a 21% reduction in STEMI admissions and longer ambulance response times (87 (62-118) min in 2020 vs 75 (57-95) min in 2019, p<0.001), but that this was not associated with a delays in achieving revascularisation once in hospital (48 (34-65) min in 2020 vs 48 (35-70) min in 2019, p=0.35) or increased mortality (10.9% (38) in 2020 vs 8.6% (38) in 2019, p=0.28). 46 patients with active COVID-19 were more thrombotic and more likely to have intensive care unit admissions (32.6% (15) vs 9.3% (28), OR 5.74 (95%CI 2.24 to 9.89), p<0.001). They also had increased length of stay (4 (3-9) days vs 3 (2-4) days, p<0.001) and a higher mortality (21.7% (10) vs 9.3% (28), OR 2.72 (95% CI 1.25 to 5.82), p=0.012) compared with patients having PPCI without COVID-19. CONCLUSION: These findings suggest that PPCI pathways can be maintained during unprecedented healthcare emergencies but confirms the high mortality of STEMI in the context of concomitant COVID-19 infection characterised by a heightened state of thrombogenicity.
Little et al. (Thu,) conducted a observational in ST-segment elevation myocardial infarction (STEMI) (n=788). Active COVID-19 infection vs. No COVID-19 infection was evaluated on In-hospital mortality (OR 2.72, 95% CI 1.25 to 5.82, p=0.012). STEMI patients with active COVID-19 had significantly higher in-hospital mortality compared to those without COVID-19 (21.7% vs 9.3%; OR 2.72; 95% CI 1.25-5.82; p=0.012).